View clinical trials related to ROS1 Rearrangement.
Filter by:This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. - This research study involves four study drugs. - Lorlatinib - Binimetinib - Crizotinib - TNO155